Abstract
Psoriasis vulgaris affects roughly 2–4% of people worldwide. Biologics aimed at IL-17A, IL-23 and TNF-α clear skin quickly, but the disease usually returns once treatment stops. After ixekizumab withdrawal, the median time to relapse is about 20.4 weeks. Persistent tissue-resident memory T cells and unresolved dermal microvascular change are the leading explanations. This narrative review asks whether combining Traditional Chinese Medicine (TCM) with biomedical treatment can delay relapse after biologic discontinuation. We drew on a prospective registry cohort, a trial protocol for the Guben Qushi Huayu formula (GQHF) plus ixekizumab, a meta-analysis of herbal bath therapy, and mechanistic and modelling papers. The registry cohort associates adjunctive Chinese herbal medicine with a lower hazard of relapse after biologic withdrawal, but its observational design leaves confounding unresolved. The GQHF randomized trial is registered, yet the sources we reviewed report no results. Evidence for acupuncture in psoriasis is indirect, and the proposed Blood Aspect correlates, relapse-prediction models and staged management framework remain untested hypotheses. Integrative care is a reasonable question to test, not an established way to prolong remission. Adequately powered, placebo-controlled trials with standardized relapse definitions and long follow-up are needed.
References
Armstrong, A. W., & Read, C. (2020). Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA, 323(19), 1945–1960.
Bachelez, H. (2015). Interleukin-17 inhibition: a route to psoriasis clearance? The Lancet, 386(9993), 510–512.
Bardazzi, F., Bonci, C., Sacchelli, L., Di Altobrando, A., Iommi, M., & Rucci, P. (2022). Suicide risk and depression in patients with psoriasis. Italian Journal of Dermatology and Venereology, 157(6), 497–501.
Blauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., et al. (2020). A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. British Journal of Dermatology, 182(6), 1348–1358.
Chen, H., Wang, X., Zheng, X., Wang, Q., Li, M., & Tang, B. (2024). Simultaneous determination of 8 components of Guben Qushi Huayu Formula and prediction of its therapeutic target for psoriasis. Chinese Traditional Patent Medicine, 46(09), 3176–3181.
Duan, W., Chen, D., Huang, Z., Zeng, Y., Liu, S., Wang, C., & Zhou, H. (2025). Biological effect of acupuncture on peripheral facial paralysis and neuro-immune inflammation. Frontiers in Neurology, 16, 1516904.
Egeberg, A., Thyssen, J. P., Wu, J. J., & Skov, L. (2019). Risk of first-time and recurrent depression in patients with psoriasis: a population-based cohort study. British Journal of Dermatology, 180(1), 116–121.
Elmets, C. A., Leonardi, C. L., Davis, D., Gelfand, J. M., Lichten, J., Mehta, N. N., et al. (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology, 80(4), 1073–1113.
Elmets, C. A., Korman, N. J., Prater, E. F., Wong, E. B., Rupani, R. N., Kivelevitch, D., et al. (2021). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities. Journal of the American Academy of Dermatology, 84(2), 432–470.
Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021). Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. The Lancet, 397(10275), 754–766.
Gordon, K. B., Colombel, J. F., & Hardin, D. S. (2016). Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. New England Journal of Medicine, 375(21), 2102.
Griffiths, C., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. (2021). Psoriasis. The Lancet, 397(10281), 1301–1315.
Han, D., & Yan, X. (2025). A new perspective on precision treatment for psoriasis based on Traditional Chinese Medicine pattern differentiation. Journal of Clinical Medicine Practice, 7(10), 15–22.
Huang, S., Duan, X. W., Zhang, H. C., Dai, B. W., & Bai, Y. P. (2024). Adjunctive Chinese medicine therapy reduces relapse of psoriasis vulgaris after discontinuation of biologics: a prospective registry-based cohort study. Journal of Dermatological Treatment, 35(1), 2355261.
Li, Z., Guan, K., Deng, H., Ye, S., Deng, J., Yao, D., Yan, Y., Chen, H., Lu, C., & Yu, J. (2025). Chinese herbal medicine (Guben Qushi Huayu formula) combined with ixekizumab in reducing psoriasis vulgaris relapse: Protocol for a mixed-methods research study. Frontiers in Pharmacology, 16, 1551001.
Masson, R. M., Shourick, J., Jendoubi, F., Tauber, M., & Paul, C. (2022). Time to relapse after discontinuing systemic treatment for psoriasis: A systematic review. American Journal of Clinical Dermatology, 23(4), 433–447.
Min, D., Fiedler, J., & Anandasabapathy, N. (2024). Tissue-resident memory cells in antitumoral immunity and chronic inflammatory diseases. Current Opinion in Immunology, 91, 102499.
Nast, A., Smith, C., Spuls, P. I., Avila, V. G., Bata-Csörgö, Z., Boonen, H., et al. (2020). EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. Journal of the European Academy of Dermatology and Venereology, 34(11), 2461–2498.
Nast, A., Altenburg, A., Augustin, M., Boehncke, W. H., Härle, P., Klaus, J., et al. (2021). German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations. Journal of the German Society of Dermatology, 19(6), 934–950.
Parisi, R., Iskandar, I., Kontopantelis, E., Augustin, M., Griffiths, C., & Ashcroft, D. M. (2020). National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ, 369, m1590.
Reich, K., Pinter, A., Lacour, J. P., Ferrandiz, C., Micali, G., French, L. E., et al. (2017). Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. British Journal of Dermatology, 177(4), 1014–1023.
Wang, J., Zhang, C. S., Zhang, A. L., Chen, H., Xue, C. C., & Lu, C. (2024). Adding Chinese herbal medicine bath therapy to conventional therapies for psoriasis vulgaris: A systematic review with meta-analysis of randomised controlled trials. Phytomedicine, 128, 155381.
Wang, X. Y., Zhang, C. L., & Wang, W. H. (2020). Time to relapse after treatment withdrawal for different biologics used to treat plaque psoriasis. Chinese Medical Journal, 133(24), 2998–3000.
World Federation of Chinese Medicine Societies. (2024). Guidelines for the integrated diagnosis and treatment of psoriasis vulgaris with Chinese and Western medicine. World Chinese Medicine, (17), 2535–2544.
Zhang, H., Liu, L., Wei, N., Wu, Y., Zhao, Y., & Lu, C. (2024). Effects of Guben Qushi Huayu formula on skin lesions and spleen water transport in a mouse model of psoriasis relapse. Chinese Journal of Integrated Traditional and Western Medicine, 44(01), 63–69.
Author information
Jalilov Dilshod — Master’s student, Xinjiang Medical University. Corresponding author. E-mail: dilshodjalilov009@gmail.com
Liu Hongxia — Head of the Department of Dermatology, The Fourth Affiliated Hospital of Xinjiang Medical University; Chief Physician, Doctoral Supervisor, Master’s Supervisor, Second-class Professor. E-mail: 1877538293@qq.com

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.